1163 completed, 333 unknown, 303 terminated, 224 recruiting. 1373 Phase 2, 566 Phase 3, 479 Phase 1, 43 Not applicable, 32 Phase 4.
Follow Docetaxel: new trials by email Literature Review of Docetaxel trials Research Report on Docetaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | AbbVie | 660 | 2027-01-06 | 2026-10-05 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors ISM5939, Cisplatin, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Not yet recruiting | InSilico Medicine Hong Kong Limited | 159 | 2026-12-30 | 2026-07-23 |
| Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) Plinabulin, Docetaxel, Placebo (matching plinabulin placebo) - Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance | Phase 3 | Not yet recruiting | BeyondSpring Pharmaceuticals Inc. | 442 | 2026-12-01 | 2026-09-29 |
| RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation - Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | Not yet recruiting | Georgetown University | 108 | 2026-12-01 | 2026-10-06 |
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 64 | 2026-11-15 | 2026-10-19 |
| A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma Iparomlimab and Tuvonralimab Injection (QL1706), Docetaxel, Oxaliplatin - Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 34 | 2026-11-01 | 2026-09-18 |
| A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients HLX22, Trastuzumab, Capecitabine - HER2 + Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Henlius Biotech | 90 | 2026-10-31 | 2026-09-17 |
| FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. FH-006, Paclitaxel, Docetaxel, Irinotecan - Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy | Phase 3 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 480 | 2026-10-10 | 2026-08-27 |
| Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients green tea and quercetin + docetaxel, Placebo + docetaxel - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Charles Drew University of Medicine and Science | 99 | 2026-10-01 | 2026-04-15 |
| ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer Aromatase inhibitor (± ovarian suppression) plus Ribociclib, 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 388 | 2026-10-01 | 2026-02-20 |
| Pathological Response to Perioperative FLOT in Gastric Adenocarcinoma FLOT Chemotherapy - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Fundación Santa Fe de Bogota | 90 | 2026-10-01 | 2026-10-05 | |
| A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy 7MW3711, Docetaxel - Lung Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 600 | 2026-10-01 | 2026-09-21 |
| A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma CRB-701, capcitabine, Cetuximab (EGFR inhibitor) - Oropharyngeal Carcinoma (OPC) | Phase 3 | Recruiting | Corbus Pharmaceuticals Inc. | 260 | 2026-09-29 | 2026-10-08 |
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2026-09-01 | 2026-06-05 |
| Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC Carboplatin, Docetaxel, Doxorubicin - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Not yet recruiting | University of Kansas Medical Center | 110 | 2026-09-01 | 2026-08-04 |
| JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer JSKN033, Docetaxel, Topotecan - Recurrent or Metastatic Cervical Cancer | Phase 3 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 368 | 2026-09-01 | 2026-09-01 |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma ATG-022, Docetaxel or Irinotecan - Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Not yet recruiting | Antengene Biologics Limited | 380 | 2026-09-01 | 2026-08-31 |
Showing 20 of 2290. Sign in to see all of them.
Breast Neoplasms (488) · Carcinoma, Non-Small-Cell Lung (447) · Prostatic Neoplasms (298) · Lung Neoplasms (171) · Stomach Neoplasms (144) · Neoplasms (118) · Squamous Cell Carcinoma of Head and Neck (113) · Neoplasm Metastasis (99) · Head and Neck Neoplasms (98) · Esophageal Neoplasms (73) · Ovarian Neoplasms (57) · Pancreatic Neoplasms (42) · Urinary Bladder Neoplasms (40) · Sarcoma (39) · Nasopharyngeal Carcinoma (36)
Sanofi (66) · Hoffmann-La Roche (63) · National Cancer Institute (NCI) (61) · M.D. Anderson Cancer Center (41) · Merck Sharp & Dohme LLC (33) · Dana-Farber Cancer Institute (32) · Eli Lilly and Company (32) · Fudan University (30) · SWOG Cancer Research Network (29) · Memorial Sloan Kettering Cancer Center (27) · Sun Yat-sen University (26) · Alliance for Clinical Trials in Oncology (25) · AstraZeneca (21) · Pfizer (21) · Hellenic Oncology Research Group (20)
United States (1100) · China (477) · France (266) · Spain (253) · Italy (227) · Germany (220) · South Korea (210) · Canada (209) · United Kingdom (184) · Belgium (150) · Australia (148) · Poland (148) · Taiwan (131) · Netherlands (118) · Japan (113)
Norman Wolmark, MD (10) · Dimitris Mavrudis, MD (7) · Edith A. Perez, MD (7) · Robert J Amato, DO (6)
PMID 34037241, PMID 24722180, PMID 40207789, PMID 28057664, PMID 33241650, PMID 35623069, PMID 36897427, PMID 37185961, PMID 38335467, PMID 38979716, PMID 40340830, PMID 10561296, PMID 10811675, PMID 15139054, PMID 15470214, PMID 17960012, PMID 17960013, PMID 19139178, PMID 19465425, PMID 20430905, PMID 21106711, PMID 22149875, PMID 22508812, PMID 22747660, PMID 23116553, PMID 24423462, PMID 2470152, PMID 25057165, PMID 26454620, PMID 27573653, PMID 28742685, PMID 29023213, PMID 29408986, PMID 29562804, PMID 30002437, PMID 30215677, PMID 30267838, PMID 30944020, PMID 30982686, PMID 31395089, PMID 31542806, PMID 32115349, PMID 32657611, PMID 33075149, PMID 33270906, PMID 33300372, PMID 33449799, PMID 34173924, PMID 34409776, PMID 34795131
2023 (34), U10CA032102 (20), 2018 (18), 2009 (16), 2014 (16), 2015 (16), P30CA043703 (15), U10CA180888 (13), 2017 (12), U10CA180820 (12), 2016 (11), P30CA022453 (11), U10CA180868 (11), 2005 (10), U10CA031946 (10)